Masoprocol - TriAct Therapeutics

Drug Profile

Masoprocol - TriAct Therapeutics

Alternative Names: INS-18; INSM-18; Masoprocal; TT-100

Latest Information Update: 27 Jul 2016

Price : $50

At a glance

  • Originator Insmed
  • Developer Insmed; University of California at San Francisco
  • Class Anti-inflammatories; Catechols; Lignans; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Insulin-like growth factor I inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 27 Jul 2016 No development reported - Phase-II for Prostate cancer in USA (PO)
  • 06 Mar 2014 Phase II development is ongoing in USA
  • 01 Jun 2011 University of California at San Francisco terminates a phase II trial in Prostate cancer in USA due to lack of efficacy (NCT00678015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top